Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

CURIA BIO INC Albany NY 12203 USA

UEI: SLED_7EE0A3C9474C6345

CURIA BIO INC Albany NY 12203 USA is a federal contractor, registered under UEI SLED_7EE0A3C9474C6345. It has been awarded $149,995,010 across 1 federal contract. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include NIH Nci.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_7EE0A3C9474C6345

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
NIH Nci$150.0M100%
Awards by NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$150.0M100%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in CURIA BIO INC Albany NY 12203 USA's top NAICS codes and agencies

NAICS: 541714
New
Federal
Hypoxia Chamber Services
Solicitation # 80JSC026Q0008
NASA Johnson Space Center is soliciting offers for Hypoxia Chamber Services under solicitation number 80JSC026Q0008 to support research on the physiological, cognitive, and clinical effects of mild hypobaric hypoxia as part of the Artemis Program. The contract requires comprehensive services including infrastructure, personnel, training, materials, food, supplies, and operational support necessary to conduct controlled hypoxia experiments. This is a combined synopsis and solicitation issued under FAR Subpart 12.6, with no written solicitation to follow, and all information is contained within the posted notice and attachments, particularly Attachment A for the Performance Work Statement and Attachment D for additional submission requirements. The NAICS code is 541714 with a size standard of 1,000 employees, and offerors must self-certify their size status. Evaluation will prioritize Technical Acceptability and Past Performance as significantly more important than Price, though Price becomes increasingly relevant when proposals are closely matched in technical merit. All submissions must include completed representations and certifications per FAR 52.212-3 and comply fully with FAR 52.212-1 and 52.212-4. Proposals must be submitted electronically via email to the designated NASA contacts no later than 1:00 PM CST on August 24, 2026, with questions due by July 29, 2026. The Government assumes no responsibility for electronic submission failures, and late submissions will be rejected per FAR provisions. The place of performance is Houston, Texas, and the Ombudsman clause is applicable for dispute resolution.
NASA Johnson Space Center

POSTED

1 day ago

DEADLINE

in 29 days
View Details
NAICS: 541714
New
Federal
Bio Molecular Systems brand Equipment to support Naval Medical Research Unit EURAFCENT
Solicitation # 1301395491
The Department of Defense, through the Navsup Flc Sigonella Naples Office, is seeking a sole-source procurement of Bio Molecular Systems brand equipment to support the Naval Medical Research Unit EURAFCENT. This acquisition, conducted under FAR Part 12 for commercial products, aims to enhance portable, forward-deployed laboratory capabilities for pathogen detection and genetic analysis in Africa and the Middle East. The required equipment includes three MicqPCR devices, one Myra device, and various associated accessories such as loading blocks, pipette heads, and filtered robot tips. All items must be new, delivered in original manufacturer packaging, and include necessary calibration certificates and software. The contract mandates delivery to DLA Distribution Sigonella in Italy within 15 calendar days of order receipt. Due to the requirement for in-country warranty support and proprietary technology, the government is pursuing a sole-source award, specifically noting that the vendor must be an authorized distributor with valid warranty coverage in Italy. Interested offerors must provide their SAM registration, Unique Entity ID, socioeconomic status under NAICS code 541714, and an official manufacturer authorization letter by August 13, 2026. The equipment carries manufacturer warranties of 36 months for the MicqPCR and 24 months for the Myra device.
Navsup Flc Sigonella Naples Office

POSTED

1 day ago

DEADLINE

in about 22 hours
View Details
NAICS: 541714
New
Federal
Hypobaric Chamber Pilot Studies
Solicitation # 80JSC026Q0006
NASA Johnson Space Center is soliciting offers for pilot chamber testing facilities capable of conducting hypobaric Decompression Sickness (DCS) studies under solicitation number 80JSC026Q0006, issued as a combined synopsis and solicitation per FAR Part 12 for commercial products and services. The requirement calls for three test days of data collection and recording following established research protocols, with detailed specifications outlined in Attachment A – Statement of Work and additional submission criteria in Attachment D dated July 15, 2026. The solicitation is open to all responsible sources without set-aside restrictions, and offerors must declare their size status under NAICS code 541714 with a 1,000-employee size standard. Evaluation of proposals will prioritize technical acceptability, followed by past performance, and then price, as specified in FAR 52.212-2. Offers must comply with applicable clauses including FAR 52.212-1, 52.212-2, and 52.212-4, as well as NASA-specific clauses such as the Ombudsman provision. All submissions must be delivered electronically to Tracy.L.Quintanilla@nasa.gov and Katelyn.R.Jaime@nasa.gov no later than August 24, 2026, at 1:00 p.m. Central Time. Questions must be submitted via email by July 29, 2026, same time, with no telephone inquiries accepted. Prospective offerors are encouraged to notify the point of contact of their intent to respond, and it is the offeror’s responsibility to download all documents from SAM.gov and ensure timely submission, as late or incomplete offers will be rejected in accordance with FAR provisions.
NASA Johnson Space Center

POSTED

1 day ago

DEADLINE

in 29 days
View Details
NAICS: 54171
New
Federal
NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAM
Solicitation # 75N98026R00109
The National Cancer Institute (NCI) is soliciting Phase I Small Business Innovation Research (SBIR) proposals under the Innovative Concept Award Program to advance research and development in therapeutic or preventative technologies, and devices, diagnostic tools, or digital health solutions for pediatric cancers and rare cancers, particularly those with a 5-year survival rate below 50%. This solicitation, numbered 75N98026R00109, is a total small business set-aside under FAR 19.5 with a NAICS code of 54171 and is open exclusively to small business concerns registered in the System for Award Management (SAM) and the SBA Company Registry, with a valid Unique Entity Identifier. Proposals must demonstrate scientific merit without requiring preliminary data, but must clearly articulate an unmet clinical need, the targeted cancer type, a viable development path, and a plan to generate initial proof-of-concept data through well-reasoned experiments. The base R&D budget is $300,000, with an optional additional $6,500 available for technical and business assistance, resulting in a potential contract value of up to $306,500. Amendments to the original solicitation have removed all requirements related to the Data Management and Sharing Plan in Sections 5.9, 6.1, and 8.5, while all other terms, conditions, and submission deadlines remain unchanged. The proposal deadline is September 21, 2026, at 5:00 p.m. Eastern Daylight Time, and submissions must be made electronically via the eCPS portal as a three-part package: a single PDF Technical Proposal including the required form and NIH biosketches, a completed Human Subjects and Clinical Trials Information Form (even if no human subjects are involved), and a single PDF Business Proposal with pricing details. Evaluation will assess technical acceptability, scientific rationale, and security risk as pass/fail gates, followed by a second review by NCI program staff. Contract administration requires electronic funds transfer for payment, mandatory SAM registration as a prerequisite for payment, and compliance with Section 508 for electronic reporting. Non-exempt human subjects research is prohibited, and all contractors must comply with human subjects protection regulations as outlined in 45 CFR part 46, maintain an active Federal-wide Assurance, and adhere to ethics, equal opportunity, E-Verify, and patent infringement reporting requirements. All awards are contingent on funding availability
NIH Nci

POSTED

2 days ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
New
Federal
Protein ENGineering (PENG)
Solicitation # DARPA-PS-26-129
The Defense Advanced Research Projects Agency (DARPA) is seeking innovative proposals under the Protein ENGineering (PENG) program, solicited through DARPA-PS-26-129, to develop a universal, software-defined platform for precise, programmable editing of endogenous proteins. The goal is to transform proteome engineering from fragmented, target-specific tools into an integrated system capable of directly recognizing, modifying, and rewriting proteins within complex biological environments using modular targeting, generalizable effector chemistries, and multiplexed control systems. Performers are expected to leverage novel splicing, ligation, and co-translational techniques to achieve these modifications in high-fidelity cellular models such as organoids, with progression from foundational validation to robust tissue-level demonstrations. The program is structured over a 42-month total period of performance, divided into an 18-month Base Phase 1, a 6-month Option Phase 1 for capability demonstration, and an 18-month Option Phase 2, spanning fiscal years 2027 through 2030. Performance will occur primarily at the contractor’s facility, with critical milestones requiring on-site demonstrations and DARPA team visits in Arlington, Virginia, where final evaluation and acceptance will take place. Proposals must adhere to strict formatting and documentation standards, including structured cost submissions using designated worksheets with sequentially numbered Reference Document IDs (e.g., EQ001, MAT010) for all equipment and materials over $5,000, supported by vendor quotes and detailed justifications. All cost estimates must comply with Federal Acquisition Regulation cost principles, and no deletion of template columns or cells is permitted. Key personnel—regardless of salary support—must be explicitly listed, and option periods must maintain continuity in document numbering with the base phase. While no explicit contract clauses, evaluation factors, or award methodology are provided, the solicitation emphasizes transparency, traceability, and compliance with Controlled Unclassified Information handling standards. Contractors must be prepared to submit proposals electronically by the October 19, 2026 deadline, with funding ceilings of up to $225,000 for Phase 1, $225,000 for Phase 2, and $160,000 for potential institutional innovation program participation, resulting in a maximum potential contract value of $610,000. No small business set-asides, socioeconomic certifications, or specific invoicing or payment office details are specified,
Defense Advanced Research Projects Agcy

POSTED

5 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Grant
PENG
Solicitation # DARPA-PS-26-129
The Defense Sciences Office within the Department of Defense is seeking innovative proposals for the development of a multifunctional, target-agnostic platform capable of precise and programmable editing of endogenous proteins. This initiative, known as PENG under solicitation DARPA-PS-26-129, aims to advance biological engineering by enabling direct, controlled modification of native proteins without relying on traditional genetic modifications or exogenous components. The platform must be adaptable across diverse protein targets, support high specificity and efficiency, and operate within complex cellular environments to facilitate robust, scalable applications. Proposals should emphasize novel mechanisms, engineering principles, and experimental validation strategies that push the boundaries of current protein editing technologies. Submissions are due by October 19, 2026, with the solicitation posted on August 7, 2026. This federal opportunity is open to organizations capable of delivering transformative research outcomes with potential national security implications. The program does not specify a set-aside type or NAICS code, and performance locations are not constrained to a particular geographic area. Interested parties are directed to the official DARPA website for full solicitation details, including evaluation criteria and technical requirements. While no point of contact information is listed publicly, all submissions must adhere to the guidelines outlined in the official solicitation document to be considered.
Defense Sciences Office

POSTED

6 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

7 days ago

DEADLINE

N/A
View Details